Cagrilintide Acetate (CAS 1415456?99?3) – Purity 99.94% GMP Factory

描述

Cagrilintide Acetate is a long?acting acylated analogue of amylin that acts as a non-selective agonist at both amylin (AMYR) and calcitonin receptors (CTR). Its prolonged half?life supports once-weekly dosing and facilitates appetite suppression and weight reduction in obesity research.

Our research-grade peptide is manufactured in GMP-compliant peptide synthesis facilities, tested to ?99.94% purity by HPLC, and shipped with full Certificate of Analysis (COA) and batch traceability. Supplied as white to off?white lyophilized powder.
?? For laboratory research use only—not intended for therapeutic or diagnostic use.

Product Specifications

Mechanism of Action & Research Applications

Cagrilintide Acetate functions as a dual agonist of amylin and calcitonin receptors, slowing gastric emptying, reducing appetite, and promoting sustained weight loss in a dose-dependent manner. It is frequently studied alone or in combination with GLP?1 agonists in obesity and metabolic research settings.

Ideal research uses include:

• Preclinical obesity and weight-loss models

• Appetite regulation and satiety studies

• Combination therapy research with GLP?1 peptides (e.g. CagriSema)

• Metabolic syndrome and diabetes-related assays

• Dual receptor pharmacology in AMYR/CTR studies

With its GMP-grade traceability and ultra-high purity, it is suitable for reproducible, regulated studies.

Side Effects (For Laboratory Reference Only)

In animal or controlled in vitro studies, observed effects may include:

• Gastrointestinal side effects (nausea, slowed digestion)

• Mild transient blood pressure changes

• Improved glycemic indices when combined with GLP?1 analogues
  Dose-controlled protocols and ethical oversight are advised.

Disclaimer

This peptide is intended strictly for laboratory research use only. It is not approved for clinical, therapeutic, or diagnostic use in humans or animals. Handle according to institutional biosafety procedures.